The Bioss team is excited to be traveling to Atlanta, GA, at the end of March for the annual meeting of the American Association for Cancer Research.

Recent findings from Northwestern University using the Bioss PPAR Gamma Polyclonal Antibody and the Bioss YWHAZ (1B6) Monoclonal Antibody shed new light on the complex network of protein interactions in patients suffering from sporadic ALS or ALS with TDP43

Via the utilization and adaption of emerging technologies, Bioss has engineered recombinant rabbit monoclonal antibodies for greater specificity and ideal target detection. Read about our process and the advantages this highlighted product line.

View Bioss' list of the best science books to pick up this season. Nine great reads to expand your mind and get you through the coldest months of the year!

View the results from the IgGy's Tower activity at SFN2018 in San Diego. With over 1400 attendees contributing, our tower contained more than 2800 Bioss bricks, each of which represents a $1 donation for our charity partners.

Dry eyes can become a serious medical concern resulting in major quality of life concerns and, in severe cases, partial or full loss of vision. New research using Bioss antibodies indicates a potential new therapy for dry eyes, which is now in phase 3 clinical trials in the U.S.